{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:55:38Z","timestamp":1777463738085,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder Cancer"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply issues underscore the importance of developing safe and effective drugs for NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>On November 18\u201319, 2021, the FDA held a public virtual workshop to discuss NMIBC research needs and potential trial designs for future development of effective therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Representatives from various disciplines including urologists, oncologists, pathologists, statisticians, basic and translational scientists, and the patient advocacy community participated. The workshop format included invited lectures, panel discussions, and opportunity for audience discussion and comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>In a pre-workshop survey, 92% of urologists surveyed considered the development of alternatives to BCG as a high drug development priority for BCG-na\u00efve high-risk patients. Key topics discussed included definitions of disease states; trial design for BCG-na\u00efve NMIBC, BCG-unresponsive carcinoma in situ, and BCG-unresponsive papillary carcinoma; strengths and limitations of single-arm trial designs; assessing patient-reported outcomes; and considerations for assessing avoidance of cystectomy as an efficacy measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The workshop discussed several important opportunities for trial design refinement in NMIBC. FDA encourages sponsors to meet with the appropriate review division to discuss trial design proposals for NMIBC early in drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/blc-230056","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:36:04Z","timestamp":1694525764000},"page":"271-286","source":"Crossref","is-referenced-by-count":7,"title":["Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer"],"prefix":"10.1177","volume":"9","author":[{"given":"Elaine","family":"Chang","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaleh","family":"Fallah","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundeep","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan A.","family":"Jaigirdar","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bross","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Sachse","sequence":"additional","affiliation":[{"name":"Bladder Cancer Advocacy Network, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie R.","family":"Brewer","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Goldstein Bladder Cancer Program, NYU Langone Health, NYU Urology Associates, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Viviano","sequence":"additional","affiliation":[{"name":"Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Bloomquist","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Ribal","sequence":"additional","affiliation":[{"name":"Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"name":"Hematology-Oncology, Icahn School of Medicine at Mount Sinai\/Tisch Cancer Institute, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Genitourinary Pathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Brothers","sequence":"additional","affiliation":[{"name":"National Cancer Institute Bladder Cancer Task Force, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Pohar","sequence":"additional","affiliation":[{"name":"Department of Urology, The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Feng","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy M.","family":"Downs","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima P.","family":"Porten","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"Bladder Cancer Advocacy Network, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Amiri-Kordestani","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Suzman","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Kluetz","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chana","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"ref002","unstructured":"BabjukM, BurgerM, Comp\u00e9ratE, et al (2022). EAU guidelines: non-muscle invasive bladder cancer. Retrieved from https:\/\/uroweb.org\/guideline\/nonmuscle-invasive-bladder-cancer\/. Access date May 27, 2022."},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.10.030"},{"key":"#cr-split#-ref005.1","unstructured":"Drugs@FDA. ADSTILADRIN (nadofaragene firadenovecvncg) suspension, for intravesical use. [updated 2022 Dec 16"},{"key":"#cr-split#-ref005.2","unstructured":"accessed 2023 Jan 2]. Available from: https:\/\/www.fda.gov\/media\/29\/download"},{"key":"#cr-split#-ref006.1","unstructured":"Drugs@FDA. KEYTRUDA (pembrolizumab) for injection, for intravenous use. [updated 2020 Jan 8"},{"key":"#cr-split#-ref006.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/\/14s066lbl.pdf"},{"key":"#cr-split#-ref007.1","unstructured":"LernerS. BCG Shortage: The Practice Environment. [PowerPoint presentation]. FDA Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). [updated 2022 Jan 18"},{"key":"#cr-split#-ref007.2","unstructured":"cited 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/155367\/download"},{"issue":"5","key":"ref008","volume":"9","author":"Cardillo F","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"ref010","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (Version 2.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 2022 Aug 9."},{"key":"ref011","unstructured":"American Urological Association. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Joint Guideline (2020). https:\/\/www.auanet.org\/guidelines\/guidelines\/bladder-cancer-non-muscle-invasive-guideline. Accessed 9 Aug 2022."},{"key":"ref012","unstructured":"Fierce Pharma. Sanofi discontinuing bladder cancer drug TheraCys after years of production issues (2016). https:\/\/www.fiercepharma.com\/manufacturing\/sanofi-discontinuing-bladder-cancer-drug-teracys-after-years-production-issues. Accessed 5 Jan 2023."},{"key":"ref013","unstructured":"Merck. Facing global shortage, Merck commits to meeting patient demand for crucial treatment option (2023). https:\/\/www.merck.com\/stories\/facing-a-global-shortage-merck-commits-to-meeting-patient-demand-for-a-crucial-treatment-option\/#:\u223c:text=In%20October%20%2C%20we%20announced,for%20patients%20who%20need%20them. Accessed 10 Aug 2023."},{"key":"ref014","unstructured":"American Urological Association. BCG Shortage Notice (2019). https:\/\/www.auanet.org\/bcg-shortage-notice. Accessed 17 Jan 2023."},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.8.597"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.04.002"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.006"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"#cr-split#-ref022.1","unstructured":"U.S. Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry. [updated 2016 Nov"},{"key":"#cr-split#-ref022.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/78504\/download"},{"key":"#cr-split#-ref023.1","unstructured":"U.S. Food and Drug Administration and International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials. General principles for planning and design of multi-regional clinical trials E17. [updated 2001 May"},{"key":"#cr-split#-ref023.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/71349\/download"},{"key":"#cr-split#-ref024.1","doi-asserted-by":"crossref","unstructured":"C.F.R. tit. 21, \u00a7 314.510. [Dec. 11, 1992","DOI":"10.2134\/jeq1992.213510x"},{"key":"#cr-split#-ref024.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-H"},{"key":"#cr-split#-ref025.1","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics. [updated 2014 May"},{"key":"#cr-split#-ref025.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/86377\/download"},{"key":"#cr-split#-ref026.1","unstructured":"U.S. Food and Drug Administration. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics | Guidance for Industry. [updated 2022 March"},{"key":"#cr-split#-ref026.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/120721\/download"},{"key":"ref027","unstructured":"Friends of Cancer Research. Pink Sheet \u2013 FDA\u2019s Pazdur Advocates Platform Trials For Cancer Drug Development (2019). https:\/\/friendsofcancerresearch.org\/news\/pink-sheet-fdas-pazdur-advocates-platform-trials-for-cancer-drug-development\/. Accessed 22 Dec 2022."},{"key":"#cr-split#-ref028.1","unstructured":"U.S. Food and Drug Administration. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. [updated 2018 Feb"},{"key":"#cr-split#-ref028.2","unstructured":"accessed 2022 Aug 9]. Available from: fda.gov\/media\/101468\/download."},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.028"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.005"},{"key":"#cr-split#-ref031.1","unstructured":"KamatA. Risk Stratification, Definitions of Disease States, and BCG Unresponsive Disease. [PowerPoint presentation]. FDA Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). [updated 2022 Jan 18"},{"key":"#cr-split#-ref031.2","unstructured":"cited 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/155373\/download"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.05.015"},{"key":"#cr-split#-ref034.1","unstructured":"U.S. Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. [updated 2018 Dec"},{"key":"#cr-split#-ref034.2","unstructured":"accessed 2022 Aug 9]. Available from: https:\/\/www.fda.gov\/media\/71195\/download"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.10.004"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3817"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.086"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.02.024"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043266"},{"key":"#cr-split#-ref040.1","unstructured":"National Library of Medicine, National Institutes of Health. ClinicalTrials.gov: Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG. [updated 2021 June 11"},{"key":"#cr-split#-ref040.2","unstructured":"accessed 2022 Nov 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02449239"},{"issue":"0","key":"ref041","first-page":"EVIDoa2200167","volume":"0","author":"Chamie K","journal-title":"NEJMEvidence"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.018"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2019.09.014"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.03.021"},{"key":"ref046","unstructured":"U.S. Food and Drug Administration. Core Patient-Reported Outcomes in Cancer Clinical Trials 2021 [Available from: https:\/\/www.fda.gov\/media\/149994\/download]"},{"key":"#cr-split#-ref047.1","unstructured":"NIH Healthcare Delivery Research Program. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [updated 2022 Jan 28"},{"key":"#cr-split#-ref047.2","unstructured":"accessed 2022 Aug 16]. Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"ref048","unstructured":"EORTC. Item Libary - Quality of Life. [accessed 2022 Aug 16]. Available from: https:\/\/qol.eortc.org\/item-library\/"},{"key":"ref049","unstructured":"HealthMeasures. PROMIS. [accessed 2023 April 4]. Available from: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis\/"},{"key":"ref050","unstructured":"FACIT. FACIT Measures & Searchable Library. [accessed 2023 April 4]. Available from: https:\/\/www.facit.org\/facit-measures-searchable-library"},{"key":"ref051","unstructured":"U.S. Food & Drug Administration. FDA Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). [accessed 2023 April 5]. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-workshop-clinical-trial-design-non-muscle-invasive-bladder-cancer-nmibc-11182021#event-materials"}],"container-title":["Bladder Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-230056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/BLC-230056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-230056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:21:24Z","timestamp":1777382484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/BLC-230056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9,1]]}},"alternative-id":["10.3233\/BLC-230056"],"URL":"https:\/\/doi.org\/10.3233\/blc-230056","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}